REFERENCES
- Mac-Kay MV, Fernandez IP, Herrera Carranza J, Sancez Burson J. An in vitro study of the influence of a drug’s molecular weight on its overall (Clt), diffusive (Cld) and convective (Clc) clearance through dialysers. Biopharm Drug Dispos. 1995;16(1):23–35.
- Hudson JQ, Comstock TJ, Feldman GM. Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant. 2004;19(2):400–405.
- Maynor LM, Carl DE, Matzke GR, . An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis. Pharmacotherapy. 2008;28(8):977–983.
- Stevenson JM, Patel JH, Churchwell MD, . Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs. 2008;31(12):1027–1034.
- Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: An in vitro study. Int J Artif Organs. 2009;32(10):745–751.
- Vilay AM, Shah KH, Churchwell MD, Patel JH, DePestel DD, Mueller BA. Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif. 2010;30(1):37–43.
- Schentag JJ, Meagher AK, Jelliffe RW. Aminoglycosides. In: Shaw LM, Burton ME, Schentag JJ, Evans WE, eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. Baltimore: Lippincott Williams and Wilkins; 2006:285–327.
- Tan CC, Lee HS, Ti TY, Lee EJ. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit. 1990;12(1):29–34.
- Fresenius Medical Care. Fresenius F180NR package insert. Waltham, MA: Fresenius Medical Care; 2007.
- Fresenius Medical Care. Fresenius F50B package insert. Waltham, MA: Fresenius Medical Care; 1996.
- Ahmed S, Misra M, Hoenich M, Daugirdas JT. Hemodialysis apparatus. In: Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007:59–78.
- Kielstein JT, Czock D, Schopke T, . Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med. 2006;34(1):51–56.
- Manley HJ, Bailie GR, McClaran ML, Bender WL. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int. 2003;63(3):1072–1078.
- Sowinski KM, Magner SJ, Lucksiri A, Scott MK, Hamburger RJ, Mueller BA. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3(2): 355–361.
- Amin NB, Padhi ID, Touchette MA, Patel RV, Dunfee TP, Anandan JV. Characterization of gentamicin pharmacokinetics in patients hemodialyzed with high-flux polysulfone membranes. Am J Kidney Dis. 1999;34(2):222–227.
- Pollard TA, Lampasona V, Akkerman S, . Vancomycin redistribution: Dosing recommendations following high-flux hemodialysis. Kidney Int. 1994;45(1):232–237.
- Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis. 1995;26(3):469–474.
- Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrol. 1998;50(1): 51–55.
- Scott MK, Mueller BA, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant. 1997;12(12):2647–2653.